Citius Oncology Secures 83% Formulary Adoption and 80% Payer Coverage for LYMPHIR
Citius Oncology has secured 83% formulary adoption for LYMPHIR across oncology centers and covered 80% of lives with 135 health plans, with repeat orders signaling growth. US field team onboarding advances commercial reach while investigator-led studies explore LYMPHIR combinations in DLBCL and solid tumors with international distribution agreements in place.
1. Commercial Launch Momentum
Since its December 2025 launch, LYMPHIR has seen sequential order growth and repeat prescriptions from leading cancer centers, indicating strong early prescribing continuity. Demand for in-services and clinical education is increasing as institutions finalize formulary inclusion.
2. Market Access Metrics
LYMPHIR has achieved formulary approval in 83% of target accounts and secured reimbursement agreements with approximately 135 health plans, representing about 80% of covered lives. There have been no reported reimbursement denials or prior authorization barriers to date.
3. Commercial Expansion
The company is onboarding its US field team this month and deploying digital campaigns, medical education programs, and engagement at major oncology meetings. International distribution agreements are in place across Europe and the Middle East to support the anticipated global demand.
4. Clinical Development Collaborations
Investigator-sponsored trials at the University of Minnesota are evaluating LYMPHIR before CAR-T therapy in relapsed/refractory DLBCL with positive topline data, while a completed Phase I study at UPMC assessed LYMPHIR with pembrolizumab in solid tumors. Further analyses and next-stage development discussions are underway.